Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including 6 and 10 weeks of age at the time of the first vaccination.~* Written informed consent obtained from the parents or guardians of the subject~* Documented HIV status of the subject as confirmed by PCR.~* HIV asymptomatic and HIV mildly symptomatic; Stages I and II disease according to WHO's most recent classification for HIV stages in infants and children.~* Born after a gestation period of 36 to 42 weeks.~Exclusion Criteria:~* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Previous routine vaccination except OPV, BCG and HBV vaccination at birth~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract or other serious medical condition as determined by the investigator.~* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.~* Acute disease at time of enrolment.~* Gastroenteritis within 7 days preceding the study vaccine administration.~* Previous confirmed occurrence of RV gastroenteritis.~* Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.~* HIV moderately and severely symptomatic: stages III and IV according to WHO's recent classification.~* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: f

Study Arms:
- Rotarix Group (Type: EXPERIMENTAL): Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.

Based on this trial design, predict the completion outcome and termination type (if applicable).